AAPL 153.04 +0.34 (+0.22%)MSFT 105 +0.23 (+0.22%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 153.04 +0.34 (+0.22%)MSFT 105 +0.23 (+0.22%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Discounted Cash Flow (DCF) Analysis Unlevered

CRISPR Therapeutics AG Quote

CRISPR Therapeu (CRSP)

29.48 2.78 Healthcare
All | Operating Data | Balance Sheet Data | Weighted Average Cost Of Capital | Build Up Free Cash | Terminal Value | Intrinsic Value | Results

Operating Data CRSP Quote CRISPR Ther

Balance Sheet Data CRSP Quote CRISPR Ther

Weighted Average Cost Of Capital CRSP Quote CRISPR Ther

Share Price $ 29.48
Diluted Shares Outstanding 20
Cost of Debt
Tax Rate -1.5
After-tax Cost of Debt -
Risk Free Rate
Market Risk Premium
Cost of Equity 20.42
Total Debt 0.00
Total Equity 1,179.20
Total Capital 1,179.20
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash CRSP Quote CRISPR Ther

Terminal Value CRSP Quote CRISPR Ther

Growth in perpetuity method:
Long term growth rate
WACC (%) 20.4
Free cash flow (t+1) 0.00
Terminal Value 0.00
Present Value of Terminal Value 0.00

Intrinsic Value CRSP Quote CRISPR Ther

Enterprise Value -
Net Debt -240
Equity Value -
Shares Outstanding 40
Equity Value Per Share -

Results Unlevered DCF CRSP Quote CRISPR Ther